



# STAAR SURGICAL CO

## FORM 8-K

(Current Report Filing)

Filed 11/01/23 for the Period Ending 11/01/23

Address 1911 WALKER AVE, MONROVIA, CA, 91016  
Telephone (727) 384-2323  
CIK 0000718937  
Symbol STAA  
SIC Code 3851 - Ophthalmic Goods  
Fiscal Year 12/30

Powered by **barchart**

<https://www.barchart.com/solutions>

© Copyright 2022, Barchart.com, Inc. All Rights Reserved.

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of  
1934**

**Date of report (Date of earliest event reported): November 1,  
2023**

**STAAR Surgical Company  
(Exact Name of Registrant as Specified in  
Charter)**

Delaware  
(State or Other Jurisdiction  
of Incorporation)

0-11634  
(Commission File Number)

95-3797439  
(IRS Employer  
Identification No.)

25651 Atlantic Ocean Drive  
Lake Forest, California  
(Address of Principal Executive Offices)

92630  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 626-303-7902**

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

## **Item 2.02 Results of Operations and Financial Condition.**

On November 1, 2023, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended September 29, 2023, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.

This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.

## **Item 9.01 Financial Statements and Exhibits**

Exhibit No.	Description
99.1	<a href="#">Press release of the Company dated November 1, 2023.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company

November 1, 2023 By: /s/ Tom Frinzi  
Thomas G. Frinzi  
President and Chief Executive Officer

---

